JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by EL-MAZATI, A. M.
Right arrow Articles by WAY, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by EL-MAZATI, A. M.
Right arrow Articles by WAY, E. L.
Journal of Pharmacology And Experimental Therapeutics, Vol. 177, Issue 2, 332-341, 1971
Copyright © 1971 by American Society for Pharmacology and Experimental Therapeutics


THE BIOLOGIC DISPOSITION OF PENTAZOCINE IN THE RAT

AZIZA M. EL-MAZATI 1 and E. LEONG WAY 1

1 Department of Pharmacology, School of Medicine, University of California, San Francisco, California

The absorption, distribution, excretion and metabolism of pentazocine were studied by a spectrophotofluorometric procedure. Oral absorption of pentazocine was rapid as evidenced by its rate of disappearance from the gastro-intestinal tract and appearance in blood and in tissues. Levels of the drug were low, however, due to rapid inactivation by the liver. After i.v. administration, pentazocine was rapidly taken up by parenchymatous tissue and was found in high concentrations in the lung, spleen, kidney and also the brain. Liver levels were high at one minute but barely detectable at 15 minutes, whereas appreciable levels were still noted in other organs for at least two hours. Very little unchanged pentazocine was excreted in urine and feces; less than 10% of the drug was accounted for as extractable fluorescent products and counter-current distribution of this material revealed that only a minor fraction could be attributed to pentazocine. The chief biotransformation products are conjugates of glucuronic acid which appear early in the bile and urine. Small amounts of pentazocine can be accounted for in urine as conjugated sulfates and as nonconjugated phenolic metabolites. No evidence for N-dealkylation of the drug to norpentazocine was obtained. Rapid and extensive metabolism of pentazocine was effected by the liver homogenate and the presence of calcium in the medium markedly inhibited the reaction.

Submitted on September 4, 1970
Accepted on January 7, 1971







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1971 by the American Society for Pharmacology and Experimental Therapeutics.